Inactive Instrument

Zymergen Inc.

Equities

ZY

US98985X1000

Biotechnology & Medical Research

Zymergen, Inc. Appoints Jay Flatley and Sandra E. Peterson to the Board of Directors

January 21, 2020 at 12:00 pm EST

Zymergen announced that it has appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to the Company’s Board of Directors, effective immediately. Mr. Flatley will serve as Lead Independent Director.

Latest news about Zymergen Inc.

Zymergen Inc. Went Out of Business	Feb. 22	CI
Liquidation Plan Approved for Zymergen Inc.	Feb. 04	CI
Motion for Exclusivity Period Extension Approved For Zymergen Inc.	Jan. 30	CI
First Motion for Exclusivity Period Extension Filed by Zymergen Inc.	Jan. 21	CI
Disclosure Statement Approved for Zymergen Inc.	Dec. 19	CI
Amended Liquidation Plan and Disclosure Statement Filed by Zymergen Inc.	Dec. 17	CI
Liquidation Plan and Disclosure Statement Filed by Zymergen Inc.	23-10-04	CI
Motion for Joint Administration Approved for Zymergen Inc.	23-10-03	CI
Motion for Asset Sale Filed by Zymergen Inc.	23-10-03	CI
Motion for Joint Administration Filed by Zymergen Inc.	23-10-03	CI
Zymergen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23-01-27	CI
Zymergen Inc.(NasdaqGS:ZY) dropped from S&P TMI Index	22-10-21	CI
Ginkgo Bioworks Holdings Closes Zymergen Acquisition	22-10-19	MT
Zymergen Inc. Announces Executive Changes	22-10-19	CI
Zymergen Inc.(NasdaqGS:ZY) dropped from NASDAQ Composite Index	22-10-19	CI
Ginkgo Bioworks Holdings, Inc. completed the acquisition of Zymergen Inc. (NasdaqGS:ZY) from a group of shareholders.	22-10-18	CI
Zymergen Says It Cut 80 More Jobs; Co-Founder Zach Serber Stepping Down as Chief Science Officer	22-08-25	MT
Zymergen Inc. Announces Stepping Down of Zach Serber as Co-Founder and Chief Science Officer and A Member of It’S Board of Directors, Effective as of September 22, 2022	22-08-25	CI
Zymergen Inc. Announces Further Reduction in Force	22-08-25	CI
Top Premarket Gainers	22-08-16	MT
Zymergen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
North American Morning Briefing : Growth Stocks -2-	22-07-27	DJ
UBS Adjusts Zymergen Price Target to $2.60 From $4, Maintains Neutral Rating	22-07-26	MT
JPMorgan Upgrades Zymergen to Neutral From Underweight	22-07-26	MT
Transcript : Ginkgo Bioworks Holdings, Inc., Zymergen Inc. - M&A Call	22-07-25

Chart Zymergen Inc.

Duration

Period

More charts

Company Profile

Zymergen Inc. integrates computational and manufacturing technologies to design, develop, and commercialize bio-based products in a range of industries. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research